A murine model of atypical antipsychotic-induced weight gain and metabolic dysregulation.
In comparison with conventional, first-generation antipsychotics (e.g., haloperidol), the administration of atypical antipsychotics (AAPs) has been associated with a higher risk of metabolic derangements, including body weight increase, dysregulation of glucose homeostasis, fat accumulation, and even liability to develop type II diabetes. Since this is a serious clinical problem that may be further exacerbated in overweight schizophrenics, establishing animal models of AAP-induced adverse effects may contribute to clarifying the mechanisms underlying these effects. Here we present three basic protocols by which this problem has been modeled. The three protocols differ in many aspects (routes of administration, extent of the chronic treatment, diets, and dosage regimen), and the pros and cons of each procedure are systematically detailed throughout. It should be noted that several factors (e.g., species, sex, duration, and class of AAPs) could restrict the feasibility of these models, as well as their correspondence to the clinical condition.
Coccurello
Roberto
R
Institute of Neuroscience, National Research Council (C.N.R.), Rome, Italy.
Moles
Anna
A
D000284:Administration, Oral; D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects; D004195:Disease Models, Animal; D004435:Eating / Q000187:drug effects; D005260:Female; D015918:Infusion Pumps, Implantable; D008659:Metabolic Diseases / Q000139:chemically induced*; D051379:Mice; D008817:Mice, Mutant Strains; D000077152:Olanzapine; D051381:Rats; D055647:Rats, Transgenic; D015430:Weight Gain / Q000187:drug effects*
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine